Navigation Links
Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
Date:10/10/2007

SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that preclinical data for its proprietary product candidate NKTR-102 (PEG-irinotecan) will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Therapeutics in San Francisco, California on October 25, 2007. The presentations will highlight new results from preclinical trials of NKTR-102 in mouse models of colorectal, lung and breast cancers. NKTR-102 is a PEGylated form of irinotecan created using Nektar's innovative small molecule PEGylation technology platform and is in Phase 1 clinical development for the treatment of solid tumors.

In preclinical studies presented at ECCO 14 in September, NKTR-102 substantially suppressed tumor growth in an irinotecan-resistant mouse colorectal tumor model, while irinotecan-treated groups did not show a statistically significant decrease in tumor growth compared to controls. Further, administration of NKTR-102 resulted in a significantly improved pharmacokinetic profile for the active metabolite of irinotecan as compared to treatment with irinotecan.

"The studies for NKTR-102 continue to indicate that Nektar's small molecule PEGylation technology can be a powerful platform for improving chemotherapeutic agents," Tim Riley, Ph.D., Vice President of PEGylation Research at Nektar. "The new preclinical data in colorectal, lung and breast tumor models also highlights the promise of NKTR-102 to serve as a potentially new and powerful therapy in multiple solid tumor settings."

Two poster presentations are scheduled:

October 25, 2007 - 12:30 PM - 2:00 PM (PT); 5:30 - 7:30 PM (PT)

Poster Session C -- AACR-NCI-EORTC
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
2. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
3. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
4. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
5. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
6. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
7. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Emerus Holdings, a national and innovative ... diagnostic care in partnership with leading health systems, ... to receive a strategic investment from Welsh, Carson, ... care investment firm. Emerus partners with ... and ambulatory clinical services to communities across a ...
(Date:9/1/2015)... -- Sleep Specialists, LLC a medical device company ... Solutions, a leader in digital health and chronic ... and cost reduction program for patients with Obstructive ... chronic medical condition characterized by periods of interrupted ... risk for cardiovascular disease, hypertension, stroke, congestive heart ...
(Date:9/1/2015)... RIVER, Mass. , Sept. 1, 2015   ... an additional 120,000 square feet in Olive Branch, ... Olive Branch facility has added the ... warehousing space. "This expansion gives us the ... Karl Neuberger , President of Millstone MS. "Two and a ...
Breaking Medicine Technology:Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3Sleep Specialists, LLC and HGE Health Care Solutions Announce Comprehensive Sleep Program 2Millstone Medical Outsourcing Announces Olive Branch Expansion 2
(Date:9/1/2015)... ... 2015 , ... According to a study published August 25th in ... in a three year study about weight loss and diabetes were far more likely ... loss surgery at the onset of the trial. In fact, the participants in the ...
(Date:9/1/2015)... ... September 01, 2015 , ... From Aug. 17-21, Calvary Hospital hosted ... ages 6-18. Calvary’s Camp Compass® has taken place at Kingsborough Community College in Brooklyn ... some of whom work for Calvary, and two junior counselors who were campers themselves ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... of the American Society for Dermatologic Surgery, according to a new survey that ... Consumer Survey on Cosmetic Dermatologic Procedures – which reflects views on cosmetic medical ...
(Date:9/1/2015)... TX (PRWEB) , ... September 01, 2015 , ... ... that it is now offering the MonaLisa Touch® , an innovative vaginal ... The MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a condition ...
(Date:9/1/2015)... ... September 01, 2015 , ... With former IBMers among its founding members, Inmar ... inception more than 35 years ago. A pilot program begun by the company in ... not just those intent on pursuing careers in these fields. The program is now ...
Breaking Medicine News(10 mins):Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 2Health News:Calvary Hospital Hosts 18th Annual Bereavement Camp 3Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2
... 18 (HealthDay News) -- Flu vaccination levels among U.S. ... are still below the 2020 national health objectives, a ... for Disease Control and Prevention also found that too ... care personnel should get an annual flu vaccination, according ...
... tumors aren,t uniform: they are more like complex societies, ... playing different roles. Understanding this "social structure" of tumors ... different cell types may be sensitive to different drugs. ... society, in which all cancer cells descend from special ...
... Fighting Drug, Vemurafenib Powerful X-Rays Enable ... Life-Threatening Diseases WASHINGTON, DC Powerful X-ray ... (DOE,s) national laboratories is revealing new insights into ... and, most recently, enabled the discovery of a ...
... , THURSDAY, Aug. 18 (HealthDay News) -- Many doctors continue ... guidelines say some women can wait much longer between tests. ... Katherine Roland, a behavioral scientist at the U.S. Centers for ... with the guidelines," Roland said. The downsides of too-frequent ...
... For the first time, researchers at Seattle Cancer ... serial positron emission tomography (PET) scans, using a ... of estrogen-blocking and estrogen-depleting therapy in patients with ... are published online in Clinical Cancer Research ...
... , WEDNESDAY, Aug. 17 (HealthDay News) -- A newer ... consciousness while under anesthesia is no better than conventional ... new research shows. In fact, the newer system ... is known as bispectral index (BIS) monitoring -- actually ...
Cached Medicine News:Health News:Flu Shot Rates Low for Health Workers, Moms-to-Be: CDC 2Health News:Cancer stem cells made, not born 2Health News:Cancer stem cells made, not born 3Health News:DOE laboratories help develop promising new cancer fighting drug, vemurafenib 2Health News:Annual Pap Tests Often Ordered But Unneeded: Study 2Health News:Annual Pap Tests Often Ordered But Unneeded: Study 3Health News:PET scans confirm effectiveness of estrogen-blocking drugs in breast cancer patients 2Health News:Method to Detect When Patients Wake During Surgery Fails to Impress 2Health News:Method to Detect When Patients Wake During Surgery Fails to Impress 3
... HT is designed for extended temperatures. ... ideal for applications such as DNA ... Incubator/Shaker HT is available as a ... three microplates. Iems Incubator/Shaker HT including ...
... are designed to give reliable performance for all ... on/off button, power supply socket and fuse holder ... unit. The speed knob is located on the ... from a minimum 950 rpm to a maximum ...
... only four-color, automated benchtop flow cytometry system ... sorting. Designed specifically to support a wide ... software instrument control, auto-sample loading, and push-button ... FACSCalibur is fully modular so it can ...
... cytometer for any kind of cell ... CyFlow SL analyzes forward and side ... to 3 fluorescence channels. Data acquisition, ... with a PC or laptop employing ...
Medicine Products: